193 related articles for article (PubMed ID: 36814835)
1. Toward real-world automated antibody design with combinatorial Bayesian optimization.
Khan A; Cowen-Rivers AI; Grosnit A; Deik DG; Robert PA; Greiff V; Smorodina E; Rawat P; Akbar R; Dreczkowski K; Tutunov R; Bou-Ammar D; Wang J; Storkey A; Bou-Ammar H
Cell Rep Methods; 2023 Jan; 3(1):100374. PubMed ID: 36814835
[TBL] [Abstract][Full Text] [Related]
2. Structural Diversity of Ultralong CDRH3s in Seven Bovine Antibody Heavy Chains.
Dong J; Finn JA; Larsen PA; Smith TPL; Crowe JE
Front Immunol; 2019; 10():558. PubMed ID: 30967877
[TBL] [Abstract][Full Text] [Related]
3. Length of the antibody heavy chain complementarity determining region 3 as a specificity-determining factor.
Barrios Y; Jirholt P; Ohlin M
J Mol Recognit; 2004; 17(4):332-8. PubMed ID: 15227640
[TBL] [Abstract][Full Text] [Related]
4. Access to ultra-long IgG CDRH3 bovine antibody sequences using short read sequencing technology.
Oyola SO; Henson SP; Nzau B; Kibwana E; Nene V
Mol Immunol; 2021 Nov; 139():97-105. PubMed ID: 34464839
[TBL] [Abstract][Full Text] [Related]
5. Trimeric gp120-specific bovine monoclonal antibodies require cysteine and aromatic residues in CDRH3 for high affinity binding to HIV Env.
Heydarchi B; Center RJ; Bebbington J; Cuthbertson J; Gonelli C; Khoury G; Mackenzie C; Lichtfuss M; Rawlin G; Muller B; Purcell D
MAbs; 2017 Apr; 9(3):550-566. PubMed ID: 27996375
[TBL] [Abstract][Full Text] [Related]
6. Preferred CDRH3 lengths for antibodies with defined specificities.
Johnson G; Wu TT
Int Immunol; 1998 Dec; 10(12):1801-5. PubMed ID: 9885900
[TBL] [Abstract][Full Text] [Related]
7. Multi-constraint computational design suggests that native sequences of germline antibody H3 loops are nearly optimal for conformational flexibility.
Babor M; Kortemme T
Proteins; 2009 Jun; 75(4):846-58. PubMed ID: 19194863
[TBL] [Abstract][Full Text] [Related]
8. The human antibody sequence space and structural design of the V, J regions, and CDRH3 with Rosetta.
Schmitz S; Schmitz EA; Crowe JE; Meiler J
MAbs; 2022; 14(1):2068212. PubMed ID: 35544469
[TBL] [Abstract][Full Text] [Related]
9. Length distribution of CDRH3 in antibodies.
Wu TT; Johnson G; Kabat EA
Proteins; 1993 May; 16(1):1-7. PubMed ID: 8497480
[TBL] [Abstract][Full Text] [Related]
10. Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions.
Sidhu SS; Li B; Chen Y; Fellouse FA; Eigenbrot C; Fuh G
J Mol Biol; 2004 Apr; 338(2):299-310. PubMed ID: 15066433
[TBL] [Abstract][Full Text] [Related]
11. Unravelling enhancement of antibody fragment stability - Role of format structure and cysteine modification.
Ma H; Ó'Fágáin C; O'Kennedy R
J Immunol Methods; 2019 Jan; 464():57-63. PubMed ID: 30468735
[TBL] [Abstract][Full Text] [Related]
12. Rearrangement of the human heavy chain variable region gene V3-23 in transgenic mice generates antibodies reactive with a range of antigens on the basis of VHCDR3 and residues intrinsic to the heavy chain variable region.
Mageed RA; Harmer IJ; Wynn SL; Moyes SP; Maziak BB; Brüggemann M; MacKworth-Young CG
Clin Exp Immunol; 2001 Jan; 123(1):1-8. PubMed ID: 11167990
[TBL] [Abstract][Full Text] [Related]
13. Repertoire Analysis of Antibody CDR-H3 Loops Suggests Affinity Maturation Does Not Typically Result in Rigidification.
Jeliazkov JR; Sljoka A; Kuroda D; Tsuchimura N; Katoh N; Tsumoto K; Gray JJ
Front Immunol; 2018; 9():413. PubMed ID: 29545810
[TBL] [Abstract][Full Text] [Related]
14. VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120.
Smith SA; Burton SL; Kilembe W; Lakhi S; Karita E; Price M; Allen S; Derdeyn CA
Front Immunol; 2018; 9():3163. PubMed ID: 30697215
[TBL] [Abstract][Full Text] [Related]
15. Reshaping the murine immunoglobulin heavy chain repertoire with bovine DH genes.
Di Y; Cai S; Zheng S; Huang J; Du L; Song Y; Zhang M; Wang Z; Yu G; Ren L; Han H; Zhao Y
Immunology; 2022 Jan; 165(1):74-87. PubMed ID: 34428313
[TBL] [Abstract][Full Text] [Related]
16. Many Routes to an Antibody Heavy-Chain CDR3: Necessary, Yet Insufficient, for Specific Binding.
D'Angelo S; Ferrara F; Naranjo L; Erasmus MF; Hraber P; Bradbury ARM
Front Immunol; 2018; 9():395. PubMed ID: 29568296
[TBL] [Abstract][Full Text] [Related]
17. Hybridization-based antibody cDNA recovery for the production of recombinant antibodies identified by repertoire sequencing.
Valdés-Alemán J; Téllez-Sosa J; Ovilla-Muñoz M; Godoy-Lozano E; Velázquez-Ramírez D; Valdovinos-Torres H; Gómez-Barreto RE; Martinez-Barnetche J
MAbs; 2014; 6(2):493-501. PubMed ID: 24492293
[TBL] [Abstract][Full Text] [Related]
18. CDR-H3 diversity is not required for antigen recognition by synthetic antibodies.
Persson H; Ye W; Wernimont A; Adams JJ; Koide A; Koide S; Lam R; Sidhu SS
J Mol Biol; 2013 Feb; 425(4):803-11. PubMed ID: 23219464
[TBL] [Abstract][Full Text] [Related]
19. Matching amino acid and nucleotide sequences of mouse rheumatoid factor CDRH3-FRH4 segments to other mouse antibodies with known specificities.
Johnson G; Wu TT
Bioinformatics; 2000 Oct; 16(10):941-3. PubMed ID: 11120684
[No Abstract] [Full Text] [Related]
20. A two-in-one antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions.
Lee CV; Koenig P; Fuh G
MAbs; 2014; 6(3):622-7. PubMed ID: 24618680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
